Yesterday, the Initiative for Medicines, Access, and Knowledge I-MAK took an important step by proposing six policy solutions to address patent thickets that block generic and biosimilar drug competition.
Pharmacy benefit managers (PBMs) are a popular Congressional target of late.
As Congress stumbles toward a government shutdown, health policy legislation continues to simmer in the background.
“The launches this month are “more of an inflection point in the market compared to what we saw in January when Amjevita came to market,” said Alex Brill.
Now that biosimilar versions of Humira are starting to arrive, what happens next? Will this finally prove the case that biosimilars can deliver on big health care savings?